Embecta (NASDAQ:EMBC – Get Free Report) posted its earnings results on Friday. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29, Zacks reports. The company had revenue of $271.70 million for the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. Embecta’s revenue for the quarter was down 8.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.12 earnings per share. Embecta updated its FY 2026 guidance to 1.800-1.900 EPS.
Here are the key takeaways from Embecta’s conference call:
- U.S. revenue fell 24.6% year over year to approximately $121 million, reflecting weaker insulin-pen prescription trends, customer and payer mix pressure, and prior-year one-time benefits. Management said its outlook assumes no further recovery or deterioration in these market factors.
- Third-quarter revenue declined 8.1% year over year to approximately $272 million, although it improved sequentially by roughly $50 million. International revenue rose 11.5% as reported, helping offset continued U.S. weakness and anticipated softness in China.
- Owen Mumford integration is progressing as planned, adding auto-injectors, pharmaceutical services, and medical devices. Embecta sees a roughly $2.4 billion auto-injector market growing at a double-digit rate, though it is not yet providing specific revenue expectations for the Adaptis platform.
- Embecta raised fiscal 2026 adjusted operating margin guidance to 23.5%–24% from 22.25%–23.25% and adjusted EPS guidance to $1.80–$1.90 from $1.55–$1.75, citing cost controls, lower taxes and interest expense, and share repurchases.
- The company generated approximately $41 million in third-quarter free cash flow, repaid $53 million of debt, and expects to repay at least $150 million during fiscal 2026. Management said continued debt reduction will remain the primary capital-allocation priority.
Embecta Stock Up 26.3%
EMBC stock traded up $0.92 during midday trading on Friday, hitting $4.42. The company’s stock had a trading volume of 5,586,683 shares, compared to its average volume of 1,179,668. Embecta has a 52-week low of $2.77 and a 52-week high of $15.55. The firm has a market capitalization of $262.24 million, a P/E ratio of 2.33 and a beta of 0.81. The firm has a 50-day simple moving average of $3.34 and a 200-day simple moving average of $6.66.
Embecta Dividend Announcement
Key Stories Impacting Embecta
Here are the key news stories impacting Embecta this week:
- Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
- Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
- Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
- Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
- Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
- Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice
Analyst Ratings Changes
A number of research firms have recently issued reports on EMBC. Wall Street Zen downgraded shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Mizuho dropped their target price on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. BTIG Research lowered Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Bank of America decreased their price target on Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research note on Monday, May 18th. Finally, Weiss Ratings lowered Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. Three equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $11.00.
View Our Latest Analysis on Embecta
Institutional Trading of Embecta
Large investors have recently modified their holdings of the stock. Larson Financial Group LLC boosted its holdings in Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after purchasing an additional 1,574 shares during the period. Tower Research Capital LLC TRC increased its holdings in Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after purchasing an additional 6,224 shares during the period. Wexford Capital LP acquired a new stake in Embecta in the 3rd quarter valued at about $94,000. Humankind Investments LLC purchased a new position in shares of Embecta in the 2nd quarter valued at about $111,000. Finally, iSAM Funds UK Ltd purchased a new position in shares of Embecta in the 3rd quarter valued at about $115,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.
Embecta Company Profile
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.
Read More
- Five stocks we like better than Embecta
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
